Tirzepatide vaistai: the UK clinical picture

What SURMOUNT-1 actually showed, and what it means in practice

The SURMOUNT-1 trial randomised 2,539 adults with obesity or overweight plus at least one weight-related condition. Participants received either tirzepatide or a placebo alongside a reduced-calorie diet and increased physical activity, for 72 weeks. At the 15 mg dose, the average reduction in body weight was around 20–21%, with some analyses reaching 22.5%. Those are not hand-picked outlier numbers; they are the trial averages reported in the NEJM publication and reflected in NICE's own appraisal. NICE noted in TA1026 that indirect comparisons across the GLP-1 class favour tirzepatide over semaglutide 2.4 mg, a finding later supported by the SURMOUNT-5 head-to-head trial published in 2025.

What the numbers do not tell you is whether they apply to you specifically. Plenty of people lose considerably less; a small number lose more. Lifestyle factors (protein intake, sleep, activity) interact with the medicine. The trial participants all received structured dietary support alongside the injection, which matters when you are reading headline figures.

One thing worth understanding: the 2.5 mg starting dose exists primarily to let your system adjust, not to drive significant weight loss. The prescriber moves you up through the schedule based on tolerability and response, and if you are curious about how the titration schedule works at higher doses, our guide to tirzepatide 10 walks through what to expect at that stage. Rushing that process carries no clinical benefit and increases side-effect risk, something our clinical team at nume explains in more detail.

Tirzepatide's mechanism sets it apart from earlier GLP-1 medicines

Older GLP-1 receptor agonists, including semaglutide, work on a single pathway. Tirzepatide binds both the GLP-1 and GIP receptors, which together regulate appetite signalling, gastric emptying and blood-sugar control. The practical result is a stronger suppression of hunger than single-agonist medicines typically produce, alongside improvements in metabolic markers including blood pressure and lipids that appear in the trial data.

This dual mechanism is why tirzepatide sits in its own class, and if you are weighing up your options it is worth reading our comparison of Mounjaro or tirzepatide to understand how the two names relate and what the differences mean for you. Understanding the mechanism also explains why the gastrointestinal side effects occur: slowing gastric emptying reduces appetite effectively, but it also means nausea, reflux and loose stools are common early in treatment. For most people these effects are most pronounced in the first few weeks at a new dose.

The MHRA granted tirzepatide a Black Triangle (▼) designation, meaning it carries additional monitoring requirements while long-term post-market safety data accumulates. That is standard for newly licensed medicines and does not indicate the medicine is unsafe; it means the regulator wants extra vigilance. Patients and prescribers can report any suspected side effects at the MHRA Yellow Card scheme.

Who can access tirzepatide in the UK, and through which route

Licensed eligibility requires a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnoea. BMI thresholds are adjusted 2.5 kg/m² downward for certain ethnic backgrounds under UK guidance. A BMI that clears the threshold is not a guarantee of suitability, the prescriber reviews the full picture including any contraindications.

NHS access is phased. NICE TA1026 set out a staged rollout: from June 2025, adults with a BMI of 40 or above and four or more qualifying conditions became eligible; from around June 2026, the BMI threshold dropped to 35. These are NHS criteria, private prescribing under the same licensed criteria has been available since Mounjaro's UK launch, with no referral or waiting list, subject to clinical assessment. If you want to understand how the costs compare across routes, the Mounjaro pricing page sets out what private treatment typically involves.

For private treatment, you do not need a GP referral. At nume, the process runs through a free clinical consultation reviewed by a GPhC-registered prescriber. If approved, the order is dispatched the same day for orders placed before midday on weekdays, your pen arrives via DPD the next working day in plain, unbranded packaging, with live tracking on your phone.

Side effects: what to expect and when to act

The most frequently reported side effects are gastrointestinal: nausea, diarrhoea, constipation, vomiting, indigestion and reflux. They are at their worst after starting treatment or stepping up to a new dose, and for most people they ease over a week or two as the body adjusts. Staying well hydrated and eating smaller meals helps; specific guidance belongs with your prescriber, not a general article.

There are rarer effects that require prompt medical attention. In January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 medicines: if you develop severe stomach pain that radiates to the back, with or without vomiting, get medical help the same day. Gallbladder problems, signs of an allergic reaction and significant dehydration from persistent vomiting or diarrhoea also warrant urgent review. Women taking oral contraceptives should add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide may reduce pill absorption, a practical detail covered in detail on our tirzepatide overview.

Tirzepatide is not recommended in pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for use in under-18s. Anyone with a history of medullary thyroid carcinoma or MEN2 syndrome should discuss the risk profile carefully with a prescriber before starting, and our page on tirzepatide l covers the licensed indications and contraindications in more detail. A full breakdown of the evidence and what to consider before treatment is available on our weight management treatment page, and if you are approaching the top of the titration schedule our tirzepatide 30 page explains what that stage of treatment involves.